Action AZN ASTRAZENECA PLC
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués AstraZeneca PLC Nasdaq

Actions

AZN

US0463531089

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 28/06/2024 		Varia. 5j. Varia. 1 janv.
77,99 USD -0,24 % Graphique intraday de AstraZeneca PLC -1,13 % +15,80 %
27/06 La FDA américaine refuse d'approuver le médicament anticancéreux "missile guidé" de Merck-Daiichi RE
26/06 Les actions européennes clôturent en baisse dans les échanges de mercredi MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Astrazeneca - Tagrisso with the addition of chemotherapy approved in China as 1st-line treatment for patients with EGFR-mutated advanced lung cancer
AQ
Astrazeneca - IMFINZI demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
AQ
Astrazeneca - Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer
AQ
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
BU
AstraZeneca : Update on Imfinzi ADJUVANT BR.31 trial
PU
AstraZeneca : Imfinzi improved EFS and OS in bladder cancer
PU
Astrazeneca - Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy in advanced or metastatic triple-negative breast cancer
AQ
Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA | Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna
AQ
AstraZeneca - IMFINZI plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
AQ
AstraZeneca : Update on CAPItello-290 Phase III trial
PU
Astrazeneca - Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
AQ
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
BU
AstraZeneca : Imfinzi plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer Form 6 K
PU
AstraZeneca : Imfinzi approved in the US for endometrial cancer
PU
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
BU
AstraZeneca : Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
PU
AstraZeneca - Farxiga approved in the US for the treatment of paediatric type-2 diabetes
AQ
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
BU
AstraZeneca : Transaction by Person Discharging Managerial Responsibilities Form 6 K
PU
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development (CRDL,JAZZ, NVO, AZN, SNY)
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action AZN
  4. Action AZN
  5. Actualités AstraZeneca PLC
  6. Communiqués